Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1

  title={Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1},
  author={Chang-Liang He and Yang-Yang Bian and Yu Xue and Ze-xian Liu and Kai-Qiang Zhou and Cui-Fang Yao and Yan Lin and Han-fa Zou and Fang Luo and Yuan-Yuan Qu and Jianyuan Zhao and Mingliang Ye and Shimin Zhao and W. C. Xu},
  journal={Scientific Reports},
In cancer cells, the mammalian target of rapamycin complex 1 (mTORC1) that requires hormonal and nutrient signals for its activation, is constitutively activated. We found that overexpression of pyruvate kinase M2 (PKM2) activates mTORC1 signaling through phosphorylating mTORC1 inhibitor AKT1 substrate 1 (AKT1S1). An unbiased quantitative phosphoproteomic survey identified 974 PKM2 substrates, including serine202 and serine203 (S202/203) of AKT1S1, in the proteome of renal cell carcinoma (RCC… 

TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5

TPI1 is found to be highly expressed in BRCA tissue and cell lines, acting as an independent indicator for prognosis in B RCA patients and may serve as a therapeutic target for BRCa.

Knockdown of Pyruvate Kinase M2 Inhibits Cell Proliferation, Metabolism, and Migration in Renal Cell Carcinoma

The overexpression of PKM2 in the proximal tubule of renal tumor tissues from 70 cases of patients with renal carcinoma is revealed, and the induction of autophagy in renal cancer cells following PKM1 knockdown is revealed.

Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells

Investigation of the anticancer effects of compound 3K on the regulation of autophagic and apoptotic pathways in SK-OV-3 suggests use of specific PKM2 inhibitors to block the glycolytic pathway and target cancer cell metabolism represents a promising therapeutic approach for treating PKM 2-overexpressing ovarian cancer.

PKM 2 Knockdown Induces Autophagic Cell Death via AKT / mTOR Pathway in Human Prostate Cancer Cells

This is the first study to show that PKM2 inhibition alters prostate cancer cell metabolism and induces autophagy, thus providing new perspectives for developing PKM 2-targeting anticancer therapies for treating prostate cancer.

Compound 3K, a Specific Pyruvate Kinase M2 Inhibitor, Induces Autophagic Cell Death through the Disruption of the Glycolytic Pathway in Ovarian Cancer Cells

The anticancer effects of compound 3K, a specific PKM2 inhibitor, on autophagic and apoptotic pathway regulation in SK-OV-3 (PKM2-overexpressing human ovarian adenocarcinoma cell line) are investigated and suggest that the use of specific PKm2 inhibitors to block the glycolytic pathway and target cancer cell metabolism represents a promising therapeutic approach.

Inhibition of PTP1B blocks pancreatic cancer progression by targeting the PKM2/AMPK/mTOC1 pathway

Findings support the notion of PTP1B as an oncogene and a promising therapeutic target for PDAC and inhibit pancreatic cancer progression in vivo.

PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis

It is demonstrated here that EGFR activation results in c-Src-mediated Cdc25A phosphorylation at Y59, which interacts with nuclear pyruvate kinase M2 (PKM2), which promotes the Warburg effect, cell proliferation and brain tumorigenesis.

Significant impact of mTORC1 and ATF4 pathways in CHO cell recombinant protein production induced by CDK4/6 inhibitor

An elevated stress response via GCN2/EIF2AK4‐ATF4 axis persisted over the treatment course, which may link mTOR to downstream responses including the unfolded protein response and autophagy to enhance proper protein folding and secretion.

PKM2 promotes cell migration and inhibits autophagy by mediating PI3K/AKT activation and contributes to the malignant development of gastric cancer

In vitro cell biological behavior, in vivo tumorigenicity studies, and primary GC samples revealed an oncogenic role for PKM2 in GC, and for those GC patients who received radical resection,PKM2 might serve as a novel prognostic biomarker and target which would allow for a new treatment strategy for GC in the clinical settings.

Targeting PRAS40: a novel therapeutic strategy for human diseases

Overall, PRAS40 is expected to be a drug target and provide a new treatment strategy for human diseases including cardiovascular disease, ischaemia-reperfusion injury, neurodegenerative disease, cancer, diabetes and other metabolic diseases.



PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding*

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding in vivo and in vitro, and this inhibition depends on PRAS40 association with raptor.

Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling

A search for substrates of a growth-promoting kinase revealed a regulatory feedback loop involved in tumor suppression, and large-scale quantitative phosphoproteomics experiments were used to define the signaling networks downstream of mTORC1 and m TORC2.

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

Components of the mTOR/HIF1α/Myc–hnRNPs/PKM2 glycolysis signaling network could be targeted for the treatment of cancer caused by an aberrant RTK/PI3K/AKT/mTOR signaling pathway.

Perturbations of the AKT signaling pathway in human cancer

Various pathogenic mechanisms contributing to activation of the AKT pathway in human malignancy as well as current pharmacologic strategies to target therapeutically components of this pathway are reviewed.

The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling

It is found that the phosphorylation response to insulin is largely mTOR dependent and that mTOR exhibits a unique preference for proline, hydrophobic, and aromatic residues at the +1 position.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

A regulatory mechanism by which the Ras/MAPK and PI3K pathways converge on the tumor suppressor tuberin to inhibit its function is unveiled.

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

It is shown that expression of PKM1, the pyruvate kinase isoform with high constitutive activity, or exposure to published small molecule PKM2 activators inhibit growth of xenograft tumors and support the notion that small molecule activation ofPKM2 can interfere with anabolic metabolism.

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

The findings suggest that tyrosine phosphorylation regulates PKM2 to provide a metabolic advantage to tumor cells, thereby promoting tumor growth.